194 related articles for article (PubMed ID: 26588872)
1. Role of the lysophosphatidylinositol/GPR55 axis in cancer.
Falasca M; Ferro R
Adv Biol Regul; 2016 Jan; 60():88-93. PubMed ID: 26588872
[TBL] [Abstract][Full Text] [Related]
2. Lysophosphatidylinositol: a novel link between ABC transporters and G-protein-coupled receptors.
Ruban EL; Ferro R; Arifin SA; Falasca M
Biochem Soc Trans; 2014 Oct; 42(5):1372-7. PubMed ID: 25233417
[TBL] [Abstract][Full Text] [Related]
3. Lysophosphatidylinositol signalling: new wine from an old bottle.
Piñeiro R; Falasca M
Biochim Biophys Acta; 2012 Apr; 1821(4):694-705. PubMed ID: 22285325
[TBL] [Abstract][Full Text] [Related]
4. The oncogenic lysophosphatidylinositol (LPI)/GPR55 signaling.
Calvillo-Robledo A; Cervantes-Villagrana RD; Morales P; Marichal-Cancino BA
Life Sci; 2022 Jul; 301():120596. PubMed ID: 35500681
[TBL] [Abstract][Full Text] [Related]
5. L-α-lysophosphatidylinositol meets GPR55: a deadly relationship.
Ross RA
Trends Pharmacol Sci; 2011 May; 32(5):265-9. PubMed ID: 21367464
[TBL] [Abstract][Full Text] [Related]
6. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation.
Piñeiro R; Maffucci T; Falasca M
Oncogene; 2011 Jan; 30(2):142-52. PubMed ID: 20838378
[TBL] [Abstract][Full Text] [Related]
7. The actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55.
Yamashita A; Oka S; Tanikawa T; Hayashi Y; Nemoto-Sasaki Y; Sugiura T
Prostaglandins Other Lipid Mediat; 2013 Dec; 107():103-16. PubMed ID: 23714700
[TBL] [Abstract][Full Text] [Related]
8. GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?
Nevalainen T; Irving AJ
Curr Top Med Chem; 2010; 10(8):799-813. PubMed ID: 20370712
[TBL] [Abstract][Full Text] [Related]
9. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands.
Kapur A; Zhao P; Sharir H; Bai Y; Caron MG; Barak LS; Abood ME
J Biol Chem; 2009 Oct; 284(43):29817-27. PubMed ID: 19723626
[TBL] [Abstract][Full Text] [Related]
10. Peptide targeting of lysophosphatidylinositol-sensing GPR55 for osteoclastogenesis tuning.
Mosca MG; Mangini M; Cioffi S; Barba P; Mariggiò S
Cell Commun Signal; 2021 Apr; 19(1):48. PubMed ID: 33902596
[TBL] [Abstract][Full Text] [Related]
11. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function.
Kargl J; Brown AJ; Andersen L; Dorn G; Schicho R; Waldhoer M; Heinemann A
J Pharmacol Exp Ther; 2013 Jul; 346(1):54-66. PubMed ID: 23639801
[TBL] [Abstract][Full Text] [Related]
12. The GPR 55 agonist, L-α-lysophosphatidylinositol, mediates ovarian carcinoma cell-induced angiogenesis.
Hofmann NA; Yang J; Trauger SA; Nakayama H; Huang L; Strunk D; Moses MA; Klagsbrun M; Bischoff J; Graier WF
Br J Pharmacol; 2015 Aug; 172(16):4107-18. PubMed ID: 25989290
[TBL] [Abstract][Full Text] [Related]
13. Lysophosphatidylinositol causes neurite retraction via GPR55, G13 and RhoA in PC12 cells.
Obara Y; Ueno S; Yanagihata Y; Nakahata N
PLoS One; 2011; 6(8):e24284. PubMed ID: 21904624
[TBL] [Abstract][Full Text] [Related]
14. The LPI/GPR55 axis enhances human breast cancer cell migration via HBXIP and p-MLC signaling.
Zhou XL; Guo X; Song YP; Zhu CY; Zou W
Acta Pharmacol Sin; 2018 Mar; 39(3):459-471. PubMed ID: 29188802
[TBL] [Abstract][Full Text] [Related]
15. GPR55-dependent and -independent ion signalling in response to lysophosphatidylinositol in endothelial cells.
Bondarenko A; Waldeck-Weiermair M; Naghdi S; Poteser M; Malli R; Graier WF
Br J Pharmacol; 2010 Sep; 161(2):308-20. PubMed ID: 20735417
[TBL] [Abstract][Full Text] [Related]
16. Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells.
Oka S; Kimura S; Toshida T; Ota R; Yamashita A; Sugiura T
J Biochem; 2010 May; 147(5):671-8. PubMed ID: 20051382
[TBL] [Abstract][Full Text] [Related]
17. Lysophosphatidylinositol Promotes Chemotaxis and Cytokine Synthesis in Mast Cells with Differential Participation of GPR55 and CB2 Receptors.
Martínez-Aguilar LM; Ibarra-Sánchez A; Guerrero-Morán DJ; Macías-Silva M; Muñoz-Bello JO; Padilla A; Lizano M; González-Espinosa C
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047288
[TBL] [Abstract][Full Text] [Related]
18. A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells.
Ford LA; Roelofs AJ; Anavi-Goffer S; Mowat L; Simpson DG; Irving AJ; Rogers MJ; Rajnicek AM; Ross RA
Br J Pharmacol; 2010 Jun; 160(3):762-71. PubMed ID: 20590578
[TBL] [Abstract][Full Text] [Related]
19. The G protein-coupled receptor 55 ligand l-α-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion.
Kallendrusch S; Kremzow S; Nowicki M; Grabiec U; Winkelmann R; Benz A; Kraft R; Bechmann I; Dehghani F; Koch M
Glia; 2013 Nov; 61(11):1822-31. PubMed ID: 24038453
[TBL] [Abstract][Full Text] [Related]
20. Lysophosphatidylinositol Induced Morphological Changes and Stress Fiber Formation through the GPR55-RhoA-ROCK Pathway.
Nakajima K; Oka S; Tanikawa T; Nemoto-Sasaki Y; Matsumoto N; Ishiguro H; Arata Y; Sugiura T; Yamashita A
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
